Precision medicine terminology is often inconsistent, technical, and overwhelming for patients and caregivers. Ready to Launch Research collaborated with a cancer nonprofit to support the development of patient-centered language for biomarker and genetic testing in cancer care.
Using mixed methods, we tested a draft lexicon through focus groups, discussion boards, and a national survey representing U.S. cancer patients and caregivers. Feedback focused on comprehension, clarity, and terminology preferences. Black and Hispanic participants were oversampled to ensure inclusive and equitable health communication insights.
The final lexicon offered clear, validated terms such as “liquid biopsy” and “cancer subtype,” preferred by patients and understood across demographics. These findings support health equity in oncology by promoting consistent, patient-friendly language for precision medicine. The lexicon is now publicly available for use by providers and nonprofits: www.CommonCancerTestingTerms.org.
